Physician profile
David R Young
NPI 1366487365
$28,090.09
in general payments reported to CMS, 2019-2025
36 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $1,522 · 2021: $2,009 · 2022: $3,010 · 2023: $9,291 · 2024: $10K · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $5,208 · Travel and Lodging: $1,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,750.00 |
| Food and Beverage | $5,207.91 |
| Travel and Lodging | $1,022.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17,685.84 | 2020-2025 | Avvigo Guidance System, Watchman Access System, Rhythmia Mapping System |
| Angiodynamics, INC. | $2,415.66 | 2021-2025 | Auryon Laser System 100-120 Vac |
| Novartis Pharmaceuticals Corporation | $1,742.27 | 2019-2025 | |
| Abiomed | $1,717.69 | 2019-2025 | Impella |
| Philips North America LLC | $818.05 | 2019-2020 | |
| Shockwave Medical, INC | $701.25 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.92 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $382.73 | 2020-2024 | Farxiga, Brilinta |
| Abbott Laboratories | $301.33 | 2022-2025 | Diamondback Coronary, Diamondback Peripheral, Coroflow |
| Amgen INC. | $295.33 | 2019-2023 | Repatha |
| Medtronic, INC. | $271.89 | 2021-2023 | Linq II |
| Merck Sharp & Dohme LLC | $197.59 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $176.34 | 2019-2024 | Xarelto |
| Penumbra, INC. | $158.03 | 2020-2022 | |
| Inari Medical, INC. | $118.38 | 2020-2021 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.